Weight-Loss Drug Wegovy Launched in China

Novo Nordisk has introduced its weight-loss medication, Wegovy, in China, following its approval by the country’s health authorities in June. This launch is expected to heighten competition with Eli Lilly, a competitor whose own widely used weight-loss therapy received regulatory clearance several months prior but has not yet become available in the world’s second-largest pharmaceutical market. In China, a nation with a population of 1.4 billion, over 180 million individuals are affected by obesity. As reported by the Chinese business news outlet Yicai, a four-injection dose of Wegovy will be priced at 1,400 yuan (£153; $194), which represents a significantly lower cost compared to its price in the United States. The Yicai report further indicates that Chinese patients will bear the entire cost of the treatment, as the medication is not currently covered by the national healthcare insurance program. Studies suggest that individuals using Wegovy may experience a reduction of over 10% of their body weight. Novo Nordisk stated on the Chinese application WeChat that its therapy “will provide a safe and effective weight loss option for overweight and obese patients in China”. Wegovy, intended for individuals with severe overweight, contains semaglutide as its active ingredient. This medication assists in regulating blood sugar, reducing appetite, and promoting a feeling of fullness in patients. Semaglutide is also the active component in Ozempic, a related drug prescribed for the management of type 2 diabetes. Nevertheless, certain users may experience adverse effects, including nausea and vomiting. Furthermore, research indicates that patients frequently regain weight after discontinuing the treatment. Wegovy became available for purchase in the United States in 2021, where a one-month supply is presently priced at $1,349. Propelled by significant social media attention and endorsements from prominent figures such as Elon Musk, the medication has subsequently seen rapid sales globally. The Medicines and Healthcare products Regulatory Agency in the UK has advised medical professionals to be vigilant for patients potentially misusing obesity injections, including Wegovy. This directive came after reports emerged of individuals who were not obese falling ill after utilizing these injections for weight reduction. The widespread demand for Wegovy has elevated its manufacturer, Novo Nordisk, to the status of Europe’s most valuable company. Its current total market capitalization exceeds $440 billion.